# Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

> **NCT04446351** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 107 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** GSK6097608
- **DRUG:** Dostarlimab
- **DRUG:** Cobolimab
- **DRUG:** Belrestotug

## Key facts

- **NCT ID:** NCT04446351
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-06-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2025-10-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04446351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04446351, "Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04446351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*